Download biomedica product listAtherosclerosis is a chronic inflammatory disease of the arterial wall leading to the formation of atherosclerotic plaques (1). It is the primary cause of cardiovascular disease, affecting millions of individuals every year. Despite advances in our understanding of the disease, the exact mechanisms involved in plaque formation are not yet fully understood.
LRG-1 promotes calcification in atherosclerosis
In an attempt to gain insight into the complex processes in the development of atherosclerosis, researchers identified for the first time the molecule Leucine-Rich Alpha-2 Glycoprotein-1 (LRG1) that contributes directly to vascular calcification in mice (2). The authors suggest that LRG1 is linked to the development of plaque complications in patients with atherosclerosis. LRG1 may be a novel therapeutic target to slow down the calcification process that remains a challenge in patients with diabetes and chronic renal failure (2). Learn more about the study: Leucine-Rich Alpha-2 Glycoprotein 1 Accumulates in Complicated Atherosclerosis and Promotes Calcification.
About Leucine-Rich α-2 Glycoprotein 1 (LRG1)
LRG1* is a protein that is primarily synthesized and secreted by the liver and immune cells. It is involved in numerous conditions including lung, kidney, and heart disease. The pathogenic roles of LRG1 in these diseases are often linked to its effects on the vasculature (3). A recent review by Dritsoula A. and colleauges summarizes the multifaceted role of LRG in disrupting the vasculature. LRG has been reported to damage blood vessels in conditions such as cancer, diabetes, chronic kidney disease, ocular disease, and lung disease. Furthermore, therapeutic targeting of LRG1 has been widely proposed as a strategy to restore quienscent endothelium and normalize vasculature (4).
*LRG also named LRG1 (leucine-rich alpha-2-glycoprotein) is a glycoprotein with a molecular mass of 38.2 kDa (https://www.uniprot.org/uniprot/P02750). It is encoded by the human gene LRG-1.
Quantification of LRG1 in human samples
LRG1 can easily be quantified in human samples (serum, plasma, urine, cell culture supernatants) with a conventional ELISA* assay method.
*The ELISA technique is an immunoassay method that provides a tool to detect or quantify the concentration of a specific analyte in a sample (serum, plasma, urine, cell-culture supernatant).
Check out the LRG1 ELISA protocol booklet – day test and our poster on “Novel ELISA for the quantification of human leucine-rich α-2 glycoprotein (LRG) in serum and plasma”
LRG ELISA – developed and manufactured by BIOMEDICA (cat. no. BI-LRG)
- Full validation – data can be found here.
- LRG values available for normal and pathological samples
- Results in 3.5 hours
- ELISA kit includes 2x controls, 7x standards (for ready standard curve)
Contact us for your special study discount!
Literature
- The changing landscape of atherosclerosis. Libby P. Nature. 2021 Apr;592(7855):524-533. PMID: 33883728.
- Leucine-Rich Alpha-2 Glycoprotein 1 Accumulates in Complicated Atherosclerosis and Promotes Calcification. Grzesiak L, Amaya-Garrido A, Feuillet G, Malet N, Swiader A, Sarthou MK, Wahart A, Ramel D, Gayral S, Schanstra JP, Klein J, Laffargue M. Int J Mol Sci. 2023 Nov 20;24(22):16537. PMID: 38003727.
- LRG1: an emerging player in disease pathogenesis. Camilli C, Hoeh AE, De Rossi G, Moss SE, Greenwood J. J Biomed Sci. 2022 Jan 21;29(1):6. PMID: 35062948.
- The disruptive role of LRG1 on the vasculature and perivascular microenvironment. Dritsoula A, Camilli C, Moss SE, Greenwood J.Front Cardiovasc Med. 2024 Apr 30;11:1386177. PMID: 38745756.